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Fibroblast Growth Factor 2 
 22 different FGF family members (10 in heart) 
 
FGF2 or basic FGF – first member of the FGF 
family identified, expressed fairly ubiquitously 
 
FGF2 expressed in all developmental stages of heart; 
found in cardiomyocytes, fibroblasts, endothelium 
 
FGF2 known functions:  Hematopoiesis 
      Angiogenesis 
      Wound Healing 
      Mesoderm Induction 
      Cell Survival/Death 
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FGF2 and Cardioprotection 
Isolated work-performing global low-flow IR injury- 
 Fgf2 KO have worsened post-ischemic function 
 Cardiac-specific human FGF2 Tg have  
  -improved post-ischemic cardiac function  
  -reduced infarct size 
 
FGF2-induced cardioprotection mediated through PKC, 
MAPK, and NOS signaling 
What is the in vivo cardioprotective 
efficacy of FGF2? 
FGF2 Knockout 
Targeted ablation of all isoforms of FGF2 
 
Viable and fertile 
 
No difference from wildtype with respect to cardiac 
morphometry, function, or vessel density 
Closed Chest Ischemia-Reperfusion 
From Dewald et al. 2004 
7 Days 
Instrumentation 
7 Days Reperfusion 
90 min Ischemia 
Echo Day 1 Echo Day 7 























n=6 *p<0.05 vs. wildtype 
Endogenous FGF2 in Cardiac 
Function Post IR Injury 
* 
* 























n=6 *p<0.05 vs. wildtype 
Echo Analysis of LV Wall Motion 
Abnormalities 
* 
Trichrome Staining of Fibrosis 
Wildtype Fgf2 KO 




























Endogenous FGF2 Effect on 
 Cardiac Hypertrophy 
Myocyte Area Staining 
Wildtype Fgf2 KO 
n=6 






























Wildtype Fgf2 KO 

























n=6 *p<0.05 vs. wildtype 




















































Analysis of capillary density and vascular remodeling at 
early time points post IR injury 
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